The company rebranded from Cyclacel Pharmaceuticals, Inc. to Bio Green Med Solution, Inc. and shifted its core business from pharmaceutical development to fire safety and protection equipment. Disposed of its pharmaceutical subsidiary, Cyclacel Limited, through creditors voluntary liquidation on January 31, 2025, resulting in a $4.9 million increase in stockholders' equity. Sold its plogosertib (Plogo) clinical program assets for $300,000, with a potential additional milestone payment of $170,000, on October 6, 2025. Acquired Fitters Sdn. Bhd., a Malaysian fire safety materials and equipment company, on September 12, 2025, issuing 699,158 common shares (19.99% of the combined company) to FITTERS Diversified Berhad. Reported total revenue of $747,000 for the year ended December 31, 2025, primarily from fire safety, a significant increase from $43,000 in 2024 (clinical trial supply). Net loss decreased to $3.0 million in 2025 from $11.2 million in 2024. Accumulated deficit reached $454.4 million as of December 31, 2025. Cash and cash equivalents were $3.5 million as of December 31, 2025, up from $3.1 million in 2024. Working capital improved significantly to a surplus of $4.924 million in 2025 from a deficit of $2.594 million in 2024. Underwent two reverse stock splits in 2025: one-for-sixteen on May 12, 2025, and one-for-fifteen on July 7, 2025, to meet Nasdaq bid price requirements. The 6% Convertible Exchangeable Preferred Stock (BGMSP) was suspended from trading on Nasdaq on March 23, 2026, and is expected to be delisted on or after April 2, 2026. Issued various series of convertible preferred stock (Series C, D, E, F) and warrants in 2025, raising approximately $6.4 million net from preferred stock issuances. Management anticipates cash and cash equivalents will meet liquidity requirements into the third quarter of 2026, with substantial doubt about continuing as a going concern beyond that without additional funding.